ACTIVE-DRUG-SEQ Trademark
Trademark Overview
On Monday, December 18, 2023, a trademark application was filed for ACTIVE-DRUG-SEQ with the United States Patent and Trademark Office. The USPTO has given the ACTIVE-DRUG-SEQ trademark a serial number of 98319210. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, October 23, 2024. This trademark is owned by Zafrens, Inc.. The ACTIVE-DRUG-SEQ trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Biotechnology and pharmaceutical research services, namely screening and discernment of the reaction of living cells to drug candidates, cellular perturbations, or various other stimuli; discernment and correlation of the functional activity of living cells to the molecular states of the cells; discernment and correlation of the transcriptional and/or translational activity of living cells to the molecular states of the cells; staining or imaging of cells to identify cells' response to stimuli; collection and sequencing or identification of the metabolic products of cells exposed to drug candidates, cellular perturbations, or various other stimuli; screening of living cells to identify cells that react to an antigen or bind to a receptor; T-cell or B-cell discovery and/or screening services; bispecific antibody screening and binding study services; in the areas of biotechnology and pharmaceutical research services.
General Information
| Serial Number | 98319210 |
| Word Mark | ACTIVE-DRUG-SEQ |
| Filing Date | Monday, December 18, 2023 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Wednesday, October 23, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Biotechnology and pharmaceutical research services, namely screening and discernment of the reaction of living cells to drug candidates, cellular perturbations, or various other stimuli; discernment and correlation of the functional activity of living cells to the molecular states of the cells; discernment and correlation of the transcriptional and/or translational activity of living cells to the molecular states of the cells; staining or imaging of cells to identify cells' response to stimuli; collection and sequencing or identification of the metabolic products of cells exposed to drug candidates, cellular perturbations, or various other stimuli; screening of living cells to identify cells that react to an antigen or bind to a receptor; T-cell or B-cell discovery and/or screening services; bispecific antibody screening and binding study services; in the areas of biotechnology and pharmaceutical research services. |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 18, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Zafrens, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
Trademark Events
| Event Date | Event Description |
| Monday, December 18, 2023 | NEW APPLICATION ENTERED |
| Monday, March 25, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 9, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, October 23, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Wednesday, October 23, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Wednesday, July 3, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, July 9, 2024 | NON-FINAL ACTION WRITTEN |
| Tuesday, July 9, 2024 | NON-FINAL ACTION E-MAILED |
